GlycoMimetics (GlycoMimetics) EBIT : $-39.28 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics EBIT?

GlycoMimetics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-9.59 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-39.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. GlycoMimetics's annualized ROC % for the quarter that ended in Dec. 2023 was -801.92%. GlycoMimetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4,133.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. GlycoMimetics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -56.73%.

GlycoMimetics EBIT Historical Data

The historical data trend for GlycoMimetics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics EBIT Chart

GlycoMimetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-61.39

-51.51

-63.45

-47.40

-39.28

GlycoMimetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-10.62	-10.94	-8.93	-9.81	-9.59

Competitive Comparison of GlycoMimetics's EBIT

For the Biotechnology subindustry, GlycoMimetics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlycoMimetics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's EV-to-EBIT falls into.

GlycoMimetics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.28 Mil.

GlycoMimetics (NAS:GLYC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

GlycoMimetics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-38.36 * ( 1 - 0% )	/	( (4.339	+	5.228)	/ 2 )
=	-38.36	/	4.7835
=	-801.92 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	53.201	-	3.243	-	( 49.408	-	max(0, 6.391	-	52.01	+	49.408	))
=	4.339

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	45.316	-	3.132	-	( 41.793	-	max(0, 6.835	-	43.791	+	41.793	))
=	5.228

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

GlycoMimetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-38.36	/	( ( (1.088 + max(-3.228, 0))	+	(0.768 + max(-4.271, 0)) )	/	2 )
=	-38.36	/	( ( 1.088	+	0.768 )	/	2 )
=	-38.36	/	0.928
=	-4,133.62 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.413)	-	(3.243	+	0	+	2.398)
=	-3.228

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.822)	-	(3.132	+	0	+	2.961)
=	-4.271

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

GlycoMimetics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-39.275	/	69.226
	=	-56.73 %

GlycoMimetics EBIT Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoMimetics (GlycoMimetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

GKO:Germany

Address

9708 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.glycomimetics.com

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

Executives

Edwin Rock	officer: Chief Medical Officer	9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn	officer: CFO	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius	director	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson	officer: SVP & Chief Commercial Officer	9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath	officer: SVP and Chief Business Officer	9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Invus Public Equities Advisors, Llc	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting	10 percent owner	CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell	10 percent owner
Harout Semerjian	director, officer: Chief Executive Officer	300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950